GE HealthCare Technologies Inc. - GEHC STOCK NEWS

GE HealthCare hosted its 2024 Investor Day at Nasdaq MarketSite, highlighting its precision care strategy and financial progress. The company announced a 17% increase in quarterly dividend to $0.035 per share. GE HealthCare reiterated its 2024 outlook with organic revenue growth of 1-2% and presented medium-term targets for 2026-2028, including 4-6% organic revenue growth and high-teens to 20%+ adjusted EBIT margin. The company emphasized its focus on innovation, AI strategy, and radiopharmaceutical growth opportunities across its segments.

GE HealthCare announced results from the COSMOS pilot study evaluating their Portrait Mobile monitoring solution in post-surgical settings. The two-phase, 250-patient study showed that 82% of alarms were considered informative or useful by clinicians, with an average of less than three alarms per patient per day. The system demonstrated effectiveness in encouraging clinical intervention while reducing alarm fatigue. Notable outcomes include approximately 25% reduction in vital sign abnormalities and 60% more oxygen therapy interventions in monitored patients compared to those with standard intermittent monitoring. The study highlights Portrait Mobile's potential to enable early detection of patient deterioration and timely clinical intervention in medical-surgical units.

GE HealthCare has received FDA 510(k) clearance for its SIGNA™ MAGNUS, a 3.0T head-only MRI scanner designed for advanced neuroimaging. The system features an innovative asymmetrical head-only gradient coil design that achieves higher gradient performance with reduced inner diameter. The technology delivers gradient amplitude and slew rate superior to conventional whole-body MRI systems, with performance levels of 300 mT/m and 750 T/m/s. The system enables shorter scan times and enhanced spatial resolution while maintaining the same power requirements as the SIGNA Premier 3.0T system. Four investigational MAGNUS systems have already been installed at major medical centers.

GE HealthCare (Nasdaq: GEHC) has announced a new initiative with AMN Healthcare to address the critical shortage of radiologic technologists in healthcare. The shortage is attributed to clinician burnout, COVID-19 impacts, and demand outpacing the number of trained professionals, with 42% of clinicians considering leaving healthcare. The collaboration combines GE HealthCare's technology training expertise across multiple imaging modalities with AMN Healthcare's workforce solutions to help healthcare providers meet staffing needs. The initiative aims to develop capacity and train the next generation of rad techs across both hospital and outpatient settings.

GE HealthCare (GEHC) and RadNet's DeepHealth announced a strategic collaboration to advance AI in medical imaging. The partnership will combine GE HealthCare's imaging expertise with RadNet's DeepHealth AI solutions to create SmartTechnology™ solutions. Their first initiative integrates DeepHealth's AI-powered SmartMammo™ with GE's Senographe Pristina™ mammography system to enhance breast cancer screening. The collaboration includes Smart Alerts, aimed at enabling rapid AI processing for potentially suspicious lesions. GE HealthCare will distribute SmartMammo and other DeepHealth solutions in the United States as part of their imaging technologies portfolio.

GE HealthCare Technologies (Nasdaq: GEHC) has announced the pricing of a secondary public offering of 13,281,302 shares of its common stock. The company will not receive any proceeds from the sale, as GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank. Following this debt-for-equity exchange, Morgan Stanley & Co. will sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers. The offering is expected to close on November 12, 2024, subject to customary conditions.

GE HealthCare Technologies (Nasdaq: GEHC) announced a secondary public offering of 13,281,302 shares of common stock. The company will not sell any shares or receive proceeds from the offering. GE Aerospace plans to exchange these shares for debt held by Morgan Stanley Bank before the offering closes. Morgan Stanley & Co. will then sell the shares to underwriters. J.P. Morgan, Citigroup, and Morgan Stanley are serving as lead joint book-running managers for the offering.

GE HealthCare (Nasdaq: GEHC) announced it will host its 2024 Investor Day on Thursday, November 21, 2024, at Nasdaq MarketSite in New York, NY. The event will feature presentations from the management team covering growth strategies, technology portfolio, and business vision. A technology showcase will be available for in-person attendees following the presentations. Registration is required for attendance. Investors can access the live webcast through the company's investor relations website, where related materials and replay will also be available.

GE HealthCare (GEHC) reported Q3 2024 financial results with revenues of $4.9 billion, up 1% year-over-year. Net income margin improved to 9.7% from 7.8%, while Adjusted EBIT margin increased to 16.3% from 15.4%. Diluted EPS rose to $1.02 from $0.83, and Free cash flow reached $651 million, up from $570 million. The company saw growth in U.S. markets and Pharmaceutical Diagnostics, offset by softness in China. The company raised the low end of its full-year 2024 Adjusted EBIT margin and Adjusted EPS guidance, while noting organic revenue growth is trending toward the lower end of the 1-2% range.